Martin Pass
Pharmaceutical drug-discovery leader who worked on AstraZeneca's oncology small-molecule programs, including the ATP-competitive mTOR kinase inhibitor AZD8055.
Chief Development Officer, Amphista · Formerly Vice President and Head of Projects, Early Oncology, AstraZeneca · Industry scientist, not an academic
Oncology drug discovery, AstraZeneca (Cheshire, England, United Kingdom) ↗
Martin Pass is a drug-discovery scientist from industry rather than a university lab. According to the page of his current company, he became a program leader in the oncology group at AstraZeneca, nominating drug candidates for the clinic and leading development, and later served as Vice President, Head of Projects in early oncology. He is now Chief Development Officer at Amphista.
The 2009 Cancer Research paper in the Atlas, led by Christine Chresta, describes AZD8055. Unlike rapamycin, which blocks only part of mTORC1, AZD8055 binds the active site of the mTOR kinase and so inhibits both mTORC1 and mTORC2, including rapamycin-resistant outputs such as 4E-BP1 phosphorylation.
The compound shrank or stopped the growth of many human tumor types in mouse models and moved into phase I clinical trials.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2009 | M | AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity CHR2009 Introduced AZD8055, an ATP-competitive mTOR kinase inhibitor that blocks mTORC1 and mTORC2 and rapamycin-resistant outputs, with antitumor activity in mouse xenografts; Pass is senior (last) author. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Martin Pass.
ShowHide
- Christine M. Chresta Cancer biologist at AstraZeneca who led the preclinical description of AZD8055, one of the first ATP-competitive mTOR kinase inhibitors to reach clinical testing
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.